Financial Data and Key Metrics - The company crossed the 10,000 case mark for the year, compared to close to 8,000 in 2023 [7] - Q3 pathology revenues reached $4.5 million, an 18% increase from Q2 [9] - Q3 Products division revenues increased by 13% over Q2, reaching $680,000 [13] - Cash burn reduced by 75% from approximately $1 million in Q3 2023 to $226,000 in Q3 2024 [19] Business Line Performance - Pathology division exceeded breakeven for the second consecutive quarter, with a goal to reach a $20 million run rate [9] - Products division is progressing towards breakeven, with three key customers in onboarding stages expected to significantly impact performance [13] - Products division is expected to become the main growth engine due to recurring revenue, customer retention, and higher margins [14][15] Market and Strategic Direction - The company aims to achieve breakeven in 2024, avoiding dilutive capital raises and focusing on organic growth [8] - Pathology division serves as a self-sustained cost-free R&D platform, supporting future product development [10] - The company plans to leverage distribution channels for product sales, increasing revenue share from distributors [17][18] Management Commentary on Environment and Outlook - Management is confident in achieving financial independence and building cash reserves through organic growth [20][21] - The company plans to enhance investor education and visibility through investor conferences, analyst coverage, and consistent performance [25][26] - Management anticipates ending the year strong and entering the next year with even stronger performance [27] Other Important Information - The company’s sales team consists of five members in the pathology division and three in the products division, with potential hiring for additional stability [11][16] - The majority of revenues are currently from direct sales, but a gradual shift towards distributor-generated revenue is expected [17] Q&A Session - No specific questions or answers were provided in the transcript [31]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-17893 ...

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of th ...

NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees. Management is confident that the practical, strategic, and economic benefit to shareholders will ultimately be positive. Retaining valuable employees in an extremely competitive industry is key to ensuring the company's continued growth and ...

Zacks Investment Research has recently initiated coverage of Precipio, Inc. (PRPO) , assigning an "Outperform" recommendation to the company's shares. This bullish stance reflects the company's path to profitability and robust positioning within the cancer diagnostics space. Precipio, currently operating from New Haven, CT, focuses on cancer diagnostics. The company, which aims to address the incidence of cancer misdiagnoses through the development of diagnostic products and services, operates clinical labo ...

Precipio, Inc. (NASDAQ:PRPO) Q2 2024 Earnings Conference Call August 19, 2024 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Operator Welcome to the Precipio Second Quarter 2024 Shareholder Update Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statemen ...

NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ET. The call will include updates on the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-1789357 (S ...

NEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to note that a small contributing factor to the cash increase was the incoming cash collections that were expected in Q1, but were delayed and received in Q2 due to the impact of the Change Healthcare hack, as previously described. With ca ...

Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division's revenues will reach more than $1.5 million per month by year end, well above its breakeven goals. About Precipio This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press ...